The International ALLIANCE COVID-19 Treatment Study

Update 31 Jan 2023: The outpatient arm of the International ALLIANCE COVID-19 Treatment Study is now closed. Thank you for your interest.
We are currently in the process of analysing the data and publishing our findings of the outpatient Study Arm.
Watch this space for any updates.

Link to our Alliance Long Covid Trial: http://niim.com.au/longcovid

_________________________________________________________________________________________________________________________

News: 26 Nov 2021  We are pleased to announce that Stage 1 of the International Alliance COVID-19 Treatment Study has now been published:

Ried K, BinJemain T, Sali A (November 25, 2021). Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, and Vitamin D3 With or Without Intravenous Vitamin C: An International, Multicenter, Randomized Trial. Cureus 13(11): e19902. link:  doi:10.7759/cureus.19902

Abstract
Stage 1 of the study took place in seven participating hospitals in Turkey. A total of 237 hospitalized patients with COVID-19 aged 22-99 years (mean: 63.3 ± 15.7 years) were enrolled in the study. Almost all patients were vitamin D deficient (97%), 55% were severely vitamin D deficient (<25 nmol/L), and 42% were vitamin D deficient (<50 nmol/L); 3% had insufficient vitamin D levels (<75 nmol/L), and none had optimal vitamin D levels.

All but one patient (99.6%; n = 236/237) treated with Hydroxychloroquine (HCQ), Azithromycin (AZM), and Zinc with or without high-dose IV vitamin C (IVC) fully recovered. Additional IVC therapy contributed significantly to a quicker recovery (15 days versus 45 days until discharge; p = 0.0069).

The study suggests that the treatment protocol of HCQ, AZM, and Zinc with or without vitamin C is safe and effective in the treatment of COVID-19, with high dose IV vitamin C leading to a significantly quicker recovery.
The observed fatality rate of 0.4% (1/237) in our study stands in contrast to a 17% fatality rate of hospitalised COVID-19 patients receiving standard care, based on a meta-analysis of 33 international studies involving 13,400 patients.

In summary, the study confirms vitamin D deficiency to be a high-risk factor of severe COVID-19 disease and hospitalization. Furthermore, the study provides evidence for HCQ, AZM, zinc, with or without Intravenous Vitamin C to be a safe and effective in the treatment of COVID-19.

___________________________________________________________________________

Investigators:
Dr Taufiq Binjemain (MD, NIIM GP)
AProf Dr Karin Ried (PhD, NIIM Research Director)
Dr Avni Sali (MD, NIIM Director)

The Trial has ethics and TGA approval and is registered on the ANZ clinical trial registry (www.anzctr.org.au) ACTRN12620000557932.

Therapies to prevent progression of COVID-19 – a multicentre international randomised trial

In-hospital protocol:
Arm 1: HCQ, AZM, Zinc (ref 1 & 2), Vit D
Arm 2: HCQ, AZM, Zinc (ref 1 & 2), Vit D  + Vit C (IVC & oral)
Arm 3: Intravenous Vitamin C (IVC)

Outpatient protocol:

HCQ:                        2 x 200 mg  for 1 day
AZM:                        500 mg on day 1 followed by 250 mg once daily for 4 days
Vitamin C:             1 gram 3x times per day (3g/day) for 14 days
Zinc Citrate:          30mg elemental zinc daily for 7-14 days
Vitamin D3:          5-10,000 IU daily (if Vitamin D levels are < 75 nmol/l)

If you don’t have any symptoms of COVID-19, but are interested in the benefits of Vitamin D, you are encouraged to

• get your Vitamin D levels measured by your local GP (or via http://imedical.com.au -> private blood test)

[/vc_column_text][/vc_column][/vc_row]